Can you elaborate on the significance of the 41% and 52% objective response rates in adults and children, respectively, from the Phase 2b ReNeu trial? How do these results compare to existing treatments for NF1-PN?

The ReNeu trial reported a median best change in tumor volume from baseline of -41% in adults and -42% in children. How does this deep and sustained reduction in tumor volume translate into clinical benefits for patients?

The trial showed significant improvements in patient-reported pain and health-related quality of life. How critical are these findings for the overall management and daily lives of NF1-PN patients?

With most adverse events being Grade 1 or 2, what can you tell us about the safety and tolerability of mirdametinib? How do these findings support the long-term use of this treatment in both adults and children?

The median time to onset of response was around 7.8 to 7.9 months, with the median duration of response not reached. How does this response time and duration impact the treatment regimen and expectations for patients?

Dermatitis acneiform, diarrhea, and nausea were among the most frequently reported treatment-related adverse events. What strategies can be employed to manage these side effects and ensure patient adherence to the treatment?

The ReNeu trial utilized blinded independent central review to confirm target tumor response. How does this methodological approach enhance the reliability and robustness of the trial results?

Given the compelling evidence from the ReNeu trial, what are the next steps for the approval and commercialization of mirdametinib? How soon can we expect this treatment to become available for NF1-PN patients?